(Q36356001)

English

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

scientific article

Statements

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). (English)
David M Goldenberg
Thomas M Cardillo
Serengulam V Govindan
Edmund A Rossi
Robert M Sharkey
18 June 2015
22496-22512

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit